Therapeutic Drug Monitoring

Amitava Dasgupta received his Ph. D in chemistry from Stanford University and completed his fellowship training in Clinical Chemistry from the Department of Laboratory Medicine at the University of Washington School of Medicine at Seattle. He is board certified in both Toxicology and Clinical Chemistry by the American Board of Clinical Chemistry. Currently, he is a tenured Full Professor of Pathology and Laboratory Medicine at the University of Kansas Medical Center and Director of Clinical Laboratories at the University of Kansas Hospital. Prior to this appointment he was a tenured Professor of Pathology and Laboratory Medicine at the University of Texas McGovern medical School from February 1998 to April 2022. He has 252 papers to his credit. He is in the editorial board of four journals including Therapeutic Drug Monitoring, Clinica Chimica Acta, Archives of Pathology and Laboratory Medicine, and Journal of Clinical Laboratory Analysis.

• Chapter 1. Introduction to Therapeutic Drug Monitoring: Frequently and Less Frequently Monitored Drugs Chapter 2. Effects of Pre-Analytical Variables in Therapeutic Drug Monitoring Chapter 3. Analytical Techniques used in Therapeutic Drug Monitoring Chapter 4. Clinical Utility of Free Drug Monitoring Chapter 5. Current Practice of Therapeutic Drug Monitoring: Dose Adjustment of Drugs using Pharmacokinetic modelsChapter 6. An Introduction to Personalized Medicine Chapter 7. Application of Ultra-High Throughput Sequencing and Microarray Technologies in Pharmacogenomics TestingChapter 8. Pharmacogenomics and Warfarin therapyChapter 9. Applications of Pharmacokinetic and Pharmacodynamic Principles to Optimize Drug Dosage Selection: Example of Antibiotic Therapy ManagementChapter 10. Guidelines for Monitoring of Vancomycin, Aminoglycosides and certain antibiotics .Chapter 11. Challenges in Therapeutic Drug Monitoring of Digoxin and other Antiarrhythmic Drugs Chapter 12. Therapeutic Drug Monitoring of Classical and Newer Anticonvulsants Chapter 13. Challenges in Therapeutic Drug Monitoring of Classical Tricyclic and Newer Antidepressants: Analytical and Pharmacogenetics ConsiderationsChapter14. Therapeutic Drug Monitoring of Selected Anticancer Drugs: Pharmacogenomics issues Chapter 15. Immunosuppressive Drug Monitoring: Limitations of Immunoassays and the Application of Liquid Chromatography Mass SpectrometryChapter 16. Biomarkers: The Link between Therapeutic Drug Monitoring and Pharmacodynamics of ImmunosuppressantsChapter 17. Therapeutic Drug Monitoring of Antiretroviral Drugs in the Management of Human Immunodeficiency Infection Chapter 18. Drug Testing in Pain ManagementChapter 19. Role of Therapeutic Drug Monitoring to Identify Clinically Significant Drug-Herbal Supplement Interaction